E3 Ligases and Deubiquitinases in GPCR downregulation
GPCR 下调中的 E3 连接酶和去泛素酶
基本信息
- 批准号:7269341
- 负责人:
- 金额:$ 25.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-08-01 至 2010-07-31
- 项目状态:已结题
- 来源:
- 关键词:Adaptor Signaling ProteinAddressAdrenergic AgentsAdrenergic ReceptorAgonistArrestinArrestinsAsthmaBindingBiologyCardiovascular systemCell Surface ReceptorsCell surfaceCellsCharacteristicsChronicCleaved cellCysteine ProteaseDegradation PathwayDeubiquitinating EnzymeDeubiquitinationDevelopmentDown-RegulationDuct (organ) structureEnzymesFamilyFluorescence Resonance Energy TransferG Protein-Coupled Receptor SignalingG-Protein-Coupled ReceptorsGoalsHeart failureIsoproterenolKidneyKnowledgeLeadLibrariesLifeLife Cycle StagesLocationLung diseasesLysineLysosomesMediatingModificationMolecularObject AttachmentPost-Translational Protein ProcessingProcessProtein OverexpressionProteinsPulmonary HypertensionRateRecyclingRegulationResearch PersonnelRoleSignal TransductionSiteSmall Interfering RNASorting - Cell MovementSpecificitySubstrate SpecificityTimeUbiquitinUbiquitinationV2 ReceptorsVasopressin ReceptorVasopressinsadapter proteinadrenergicantidiureticattenuationbasebeta-2 Adrenergic Receptorsbeta-arrestincell typedesignmembermutantnovelnovel therapeuticspreventprogramsreceptorreceptor downregulationreceptor internalizationresearch studyresponsetraffickingubiquitin-protein ligaseubiquitin-specific protease
项目摘要
DESCRIPTION (provided by applicant): The beta 1 and beta 2 adrenergic receptors are members of the super-family of G protein-coupled receptors (GPCRs). This receptor super-family comprises some of the most important pharmacological targets for the treatment of cardiovascular (e.g. heart failure, hypertension) and pulmonary diseases (e.g. asthma). A major cause for the observed attenuation of adrenergic response in heart failure and asthma is receptor downregulation, which results from chronic agonist exposure. Recently, ubiquitination of cell-surface receptors has been implicated as an important mechanism for post-endocytic sorting to lysosomes. Ubiquitination is a post-translational modification of proteins orchestrated by a well-defined process involving a cascade of three enzymatic activities. Of these the final step, catalyzed by the enzyme, E3 ubiquitin ligase, determines the specificity of substrate ubiquitination. We have demonstrated that two representative GPCRs, the beta2 adrenergic receptor and the V2 vasopressin receptor and their adaptor protein beta-arrestin become ubiquitinated upon agonist stimulation. Ubiquitination of beta-arrestin is crucial for receptor internalization, whereas ubiquitination of the receptor is essential for the proper sorting and downregulation of the internalized and activated receptors. We hypothesize that ubiquitination and deubiquitination coordinate the trafficking and signaling of GPCRs and involve a specific set of endocytic adapter proteins including beta-arrestins. The specific aims are: 1) to define the molecular mechanisms of receptor ubiquitination leading to receptor downregulation, and 2) to determine the roles of deubiquitinating enzyme(s) in receptor trafficking. Unraveling the molecular mechanisms governing the regulation of GPCRs, especially beta ARs, by ubiquitination could have a great impact on the development of novel therapeutic strategies for cardiovascular and pulmonary diseases.
描述(由申请人提供):β 1和β 2肾上腺素能受体是G蛋白偶联受体(GPCR)超家族的成员。该受体超家族包括用于治疗心血管疾病(例如心力衰竭、高血压)和肺部疾病(例如哮喘)的一些最重要的药理学靶标。在心力衰竭和哮喘中观察到的肾上腺素能反应减弱的主要原因是受体下调,这是由慢性激动剂暴露引起的。最近,细胞表面受体的泛素化被认为是溶酶体内吞后分选的重要机制。泛素化是蛋白质的翻译后修饰,其由涉及三种酶活性级联的明确定义的过程协调。其中,由酶E3泛素连接酶催化的最后一步决定底物泛素化的特异性。我们已经证明,两个代表性的GPCR,β 2肾上腺素能受体和V2加压素受体和它们的衔接蛋白β-arrestin激动剂刺激后变得泛素化。β-抑制蛋白的泛素化对于受体内化是至关重要的,而受体的泛素化对于内化和活化的受体的正确分选和下调是必不可少的。我们假设泛素化和去泛素化协调GPCR的运输和信号传导,并涉及一组特定的内吞衔接蛋白,包括β-arrestins。具体目标是:1)确定受体泛素化导致受体下调的分子机制,和2)确定去泛素化酶在受体运输中的作用。揭示通过泛素化调控GPCR,特别是β AR的分子机制可能对心血管和肺部疾病的新治疗策略的发展产生重大影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SUDHA K SHENOY其他文献
SUDHA K SHENOY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SUDHA K SHENOY', 18)}}的其他基金
Regulation of myocardial GPCRs by USP20 in normal and hypertrophied heart
USP20 对正常和肥厚心脏中心肌 GPCR 的调节
- 批准号:
10427441 - 财政年份:2021
- 资助金额:
$ 25.89万 - 项目类别:
Regulation of myocardial GPCRs by USP20 in normal and hypertrophied heart
USP20 对正常和肥厚心脏中心肌 GPCR 的调节
- 批准号:
10317884 - 财政年份:2021
- 资助金额:
$ 25.89万 - 项目类别:
Regulation of myocardial GPCRs by USP20 in normal and hypertrophied heart
USP20 对正常和肥厚心脏中心肌 GPCR 的调节
- 批准号:
10630331 - 财政年份:2021
- 资助金额:
$ 25.89万 - 项目类别:
E3 Ligases and Deubiquitinases in GPCR downregulation
GPCR 下调中的 E3 连接酶和去泛素酶
- 批准号:
7837166 - 财政年份:2009
- 资助金额:
$ 25.89万 - 项目类别:
E3 Ligases and Deubiquitinases in GPCR Down Regulation
GPCR 下调中的 E3 连接酶和去泛素酶
- 批准号:
8280416 - 财政年份:2005
- 资助金额:
$ 25.89万 - 项目类别:
E3 Ligases and Deubiquitinases in GPCR downregulation
GPCR 下调中的 E3 连接酶和去泛素酶
- 批准号:
7643479 - 财政年份:2005
- 资助金额:
$ 25.89万 - 项目类别:
E3 Ligases and Deubiquitinases in GPCR downregulation
GPCR 下调中的 E3 连接酶和去泛素酶
- 批准号:
7100938 - 财政年份:2005
- 资助金额:
$ 25.89万 - 项目类别:
E3 Ligases and Deubiquitinases in GPCR downregulation
GPCR 下调中的 E3 连接酶和去泛素酶
- 批准号:
7477764 - 财政年份:2005
- 资助金额:
$ 25.89万 - 项目类别:
E3 Ligases and Deubiquitinases in GPCR Down Regulation
GPCR 下调中的 E3 连接酶和去泛素酶
- 批准号:
7987494 - 财政年份:2005
- 资助金额:
$ 25.89万 - 项目类别:
E3 Ligases and Deubiquitinases in GPCR Down Regulation
GPCR 下调中的 E3 连接酶和去泛素酶
- 批准号:
8688312 - 财政年份:2005
- 资助金额:
$ 25.89万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 25.89万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 25.89万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 25.89万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 25.89万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 25.89万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 25.89万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 25.89万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 25.89万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 25.89万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 25.89万 - 项目类别:
Research Grant